Meeting
2020 ASCO Virtual Scientific Program
ctDNA levels before treatment predict survival in non-small cell lung cancer patients treated with a tyrosine kinase inhibitor.
Authors
Mariano Provencio-Pulla
Department of Medical Oncology, University Hospital Puerta de Hierro-Majadahonda, Madrid, Spain
Mariano Provencio-Pulla , Roberto Serna , Fernando Franco , Alfredo Sanchez , Carlos García Girón , Manuel Domine , Carlos Camps , Jose Miguel Sanchez Torres , Juana Maria Oramas Rodriguez , Luis Enrique Chara Velarde , Ana Laura Ortega , María Ángeles Sala , Berta Hernandez , Maria Sereno , Joaquim Bosch-Barrera , Airam Padilla , Jose Balsalobre Yago , Remei Blanco , Javier De Castro , Atocha Romero
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9542)
DOI
10.1200/JCO.2020.38.15_suppl.9542
Abstract #
9542
Poster Bd #
308
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2019 ASCO Annual Meeting
Quantification of circulating free and circulating tumor DNA in pretreated EGFR mutant NSCLC to inform patient outcomes.
First Author: Alexandra Pender
Poster
2024 ASCO Annual Meeting
A multicenter, prospective phase II trial of first-line osimertinib treatment for patients with poor performance status and EGFR mutation–positive non-small cell lung cancer (OPEN/TORG2040).
First Author: Nobuaki Mamesaya